Cargando…

A Trial Protocol of Precision Medicine for Patients with RAS Wild Metastatic Colorectal Cancer Using Liquid Biopsy (RAS-liquid Study): A Prospective, Multicenter Observational Study

BACKGROUND: Anti-epidermal growth factor receptor (EGFR) therapy has been identified to prolong the survival of metastatic colorectal cancer (mCRC) patients without RAS mutations. However, its efficacy is not always consistent for these patients. Genomic profiles of primary tumors and metastases are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsuda, Akihisa, Yamada, Takeshi, Takahashi, Takao, Hirata, Keiji, Nagasaka, Takeshi, Ishimaru, Kei, Sakamoto, Kazuhiro, Koda, Keiji, Ishikawa, Toshiaki, Ishida, Hideyuki, Matsuda, Kenji, Kuramochi, Hidekazu, Yoshida, Yoichiro, Sonoda, Hiromichi, Yoshida, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japan Society of Coloproctology 2022
Materias:	Trial Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801244/ https://www.ncbi.nlm.nih.gov/pubmed/35128137 http://dx.doi.org/10.23922/jarc.2021-042

Ejemplares similares

A Trial Protocol of Biweekly TAS-102 and Bevacizumab as Third-Line Chemotherapy for Advanced/Recurrent Colorectal Cancer: A Phase II Multicenter Clinical Trial (The TAS-CC4 Study)
por: Yoshida, Yoichiro, et al.
Publicado: (2019)

A Trial Protocol to Investigate the Incidence of Postoperative Bowel Obstruction after Laparoscopic Colorectal Cancer Surgery Using an Absorbable Adhesion Barrier Material (INTERCEED(Ⓡ)) (Balsam CEED Study): A Prospective, Multicenter, Observational Study
por: Sonoda, Hiromichi, et al.
Publicado: (2021)

Risk of emergency surgery for complicated appendicitis: Japanese nationwide study
por: Yamada, Takeshi, et al.
Publicado: (2020)

Patient backgrounds and short‐term outcomes of complicated appendicitis differ from those of uncomplicated appendicitis
por: Oba, Takuya, et al.
Publicado: (2021)

Genetic Alterations in Ulcerative Colitis‐associated Neoplasia Focusing on APC, K‐ras Gene and Microsatellite Instability
por: Umetani, Naoyuki, et al.
Publicado: (1999)

Temporally-regulated quick activation and inactivation of Ras is important for olfactory behaviour
por: Uozumi, Takayuki, et al.
Publicado: (2012)

Low Incidence of Point Mutation of c‐Ki‐ras and N‐ras Oncogenes in Human Hepatocellular Carcinoma
por: Tsuda, Hitoshi, et al.
Publicado: (1989)

Prognostic and predictive value of extended RAS mutation and mismatch repair status in stage III colorectal cancer
por: Sasaki, Yusuke, et al.
Publicado: (2016)

The Phase II Study of Panitumumab in Chemotherapy-Naïve Frail or Elderly Patients with RAS Wild-type Colorectal Cancer: OGSG 1602 Final Results
por: Terazawa, Tetsuji, et al.
Publicado: (2022)

Dynamic regulation of RAS and RAS signaling
por: Kolch, Walter, et al.
Publicado: (2023)

Phase II Study of Panitumumab in RAS Wild‐Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater
por: Gulhati, Pat, et al.
Publicado: (2017)

Transformation of NIH3T3 Cells with Synthetic c‐Ha‐ras Genes
por: Kamiya, Hiroyuki, et al.
Publicado: (1989)

Systemic Chemotherapy is a Promising Treatment Option for Patients with Colonic Stents: A Review
por: Matsuda, Akihisa, et al.
Publicado: (2021)

Clinical impact of laparoscopic surgery and adhesion prevention material for prevention of small bowel obstruction
por: Yamada, Takeshi, et al.
Publicado: (2022)

Liquid Biopsies in Progressing Metastatic Colorectal Cancer- Application and their Therapeutic Implications According to the RAS Status
por: Pereira, José, et al.
Publicado: (2020)

Involvement of APC and K-ras mutation in non-polypoid colorectal tumorigenesis
por: Umetani, N, et al.
Publicado: (2000)

Prognostic Significance of p53 and ras Gene Abnormalities in Lung Adenocarcinoma Patients with Stage I Disease after Curative Resection
por: Isobe, Takeshi, et al.
Publicado: (1994)

Lipid Profiles of RAS Nanoclusters Regulate RAS Function
por: Zhou, Yong, et al.
Publicado: (2021)

The Role of Wild-Type RAS in Oncogenic RAS Transformation
por: Sheffels, Erin, et al.
Publicado: (2021)

Analysis of colorectal cancer‐related mutations by liquid biopsy: Utility of circulating cell‐free DNA and circulating tumor cells
por: Takeda, Kohki, et al.
Publicado: (2019)

Elucidation of ubiquitin-conjugating enzymes that interact with RBR-type ubiquitin ligases using a liquid–liquid phase separation–based method
por: Hayashida, Ryota, et al.
Publicado: (2022)

Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer
por: Klein-Scory, Susanne, et al.
Publicado: (2020)

Evaluation of RAS Mutational Status in Liquid Biopsy to Monitor Disease Progression in Metastatic Colorectal Cancer Patients
por: Lastraioli, Elena, et al.
Publicado: (2023)

Ras on the inside
por: LeBrasseur, Nicole
Publicado: (2002)

Escorting Ras
por: Zheng, Ze-Yi, et al.
Publicado: (2012)

Local RAS
por: Leung, Po Sing
Publicado: (2010)

RAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally
por: Miller, Mark Steven, et al.
Publicado: (2012)

Mechanisms of Ras Membrane Organization and Signaling: Ras Rocks Again
por: Abankwa, Daniel, et al.
Publicado: (2020)

RAS Dimers: The Novice Couple at the RAS-ERK Pathway Ball
por: Herrero, Ana, et al.
Publicado: (2021)

The NF2 tumor suppressor merlin interacts with Ras and RasGAP, which may modulate Ras signaling
por: Cui, Yan, et al.
Publicado: (2019)

Performance of Idylla(™) RAS-BRAF mutation test for formalin-fixed paraffin-embedded tissues of colorectal cancer
por: Makutani, Yusuke, et al.
Publicado: (2022)

Long‐term outcomes between self‐expandable metallic stent and transanal decompression tube for malignant large bowel obstruction: A multicenter retrospective study and meta‐analysis
por: Matsuda, Akihisa, et al.
Publicado: (2023)

REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer
por: Nakajima, Hiromichi, et al.
Publicado: (2021)

ZEB1 and oncogenic Ras constitute a regulatory switch for stimulus‐dependent E‐cadherin downregulation
por: Otake, Shigeo, et al.
Publicado: (2020)

The Ras Target AF-6 is a Substrate of the Fam Deubiquitinating Enzyme
por: Taya, Shinichiro, et al.
Publicado: (1998)

RAS Mutation Conversion in Bevacizumab-Treated Metastatic Colorectal Cancer Patients: A Liquid Biopsy Based Study
por: Nicolazzo, Chiara, et al.
Publicado: (2022)

Single‐Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)
por: García‐Alfonso, Pilar, et al.
Publicado: (2018)

DA-Raf1, a competent intrinsic dominant-negative antagonist of the Ras–ERK pathway, is required for myogenic differentiation
por: Yokoyama, Takashi, et al.
Publicado: (2007)

Cell Density-Dependent Increase in Tyrosine-Monophosphorylated ERK2 in MDCK Cells Expressing Active Ras or Raf
por: Kawabata, Noriyuki, et al.
Publicado: (2016)

Graded inhibition of oncogenic Ras-signaling by multivalent Ras-binding domains
por: Augsten, Martin, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_r48mn1mteidc74jv4njdhl8d85